Bionovo Inc. (BNVI) Stock Quote

Detailed Quote for Bionovo Inc. (BNVI)

close 52 Week Information

52 Week High

July 22, 2011

Close: 1.03

52 Week Low

February 9, 2012

Close: 0.112

Today

Last Price
0.1152

Change $
0.0002

Change %
0.17%

Tick

Bid
N/A

Bid Size
0

Ask
N/A

Ask Size
0

Open
0.115

High
0.129

Low
0.115

Prev Close
0.115

Last Trade
3:22

Volume
260.57 k

52 Wk Hi
1.03

52 Wk Low
0.112

Market Cap
6.29 m

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
54,561,312

EPS (TTM)
-0.43

PE Ratio
N/A

close Exchange Information Listed On OTCQB - U.S. Registered (OTCQB) Exchange
OTCQB

News and Media for Bionovo Inc. (BNVI)

Sector News | Topic News

News for BNVI

Tue, Feb 07, 2012

8:00 AM

Bionovo Announces Findings of Bezielle(tm) Anticancer Properties and Active Principles - PR Newswire

Fri, Jan 27, 2012

4:15 PM

Bionovo to Voluntarily Delist from NASDAQ - PR Newswire

Thu, Jan 05, 2012

8:00 AM

Robert Farrell Joins Bionovo's Board of Directors - PR Newswire

Wed, Jan 04, 2012

8:00 AM

Bionovo Appoints New Senior Vice President and Chief Financial Officer - PR Newswire

Tue, Jan 03, 2012

8:00 AM

Bionovo Announces $5 Million Financing - PR Newswire

Thu, Dec 08, 2011

8:00 AM

Bionovo Announces the Publication of its Tissue Selective Estrogen Receptor Modulators for Postmenopausal Obesity - PR Newswire

Wed, Nov 16, 2011

12:22 PM

Bionovo Announces "First Patient, First Dose" in Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes - PR Newswire

Thu, Nov 10, 2011

4:01 PM

Bionovo Announces Third Quarter 2011 Highlights and Financial Results - PR Newswire

Wed, Oct 26, 2011

4:38 PM

Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes - PR Newswire

Tue, Sep 20, 2011

8:00 AM

Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society - PR Newswire

Mon, Sep 19, 2011

8:00 AM

Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaq's Bid Price Rule - PR Newswire

Tue, Aug 30, 2011

8:00 AM

Bionovo Announces Positive Results of the Tolerability Trial of Menerba (MF101) for Menopausal Hot Flashes - PR Newswire

Mon, Aug 29, 2011

8:00 AM

Bionovo to Host a Conference Call to Discuss Menerba's Tolerability Trial Results - PR Newswire

More News for BNVI >>

Tags for Bionovo Inc.

Research stocks or mutual funds related to Bionovo Inc. by keywords or tags. Find companies that have a similar focus to BNVI. The keywords below have been associated to BNVI by either user submission or electronic means.

lung cancer dogs australia patent clinical trial logistics clinical trials liability breast cancer foundations breast cancer organizations clinical research trial breast cancer genes stage iv breast cancer breast cancer images stage 4 cancer brain cancer stage 4 symptoms of menopause pancreatic cancer diet clinical development causes of breast cancer clinical pharmacology clinical courses indiana patent patent brokerage breast and ovarian cancer clinical applications financial statements annual report patents security breast cancer cells about breast cancer pancreatic cancer symptom breast cancer causes breast cancer males clinical research training estrogen receptor pancreatic cancer treatments clinical nurse specialist stage 4 breast cancer survival breast cancer support groups Biological Products patent filing invasive breast cancer breast cancer alternative treatments corporate governance clinical psychology career breast cancer staging diabetes clinical trial breast cancer detection selling intellectual property pancreatic cancer cancer news patent protection clinical research